Posted by Michael Wonder on 02 Mar 2022
Shionogi files for approval of S-217622, a therapeutic drug for COVID-19, in Japan
25 February 2022 - Shionogi today announced that Shionogi has completed the analysis of primary endpoints a), b) in the Phase 2b part of a Phase 2/3 clinical trial of S-217622, an orally administered anti-viral drug for COVID-19, and has filed for manufacture and sales approval, requesting review under the conditional approval system in Japan.
This Phase 2b part of the Phase 2/3 clinical trial is a randomised, placebo-controlled, double-blind study in 428 SARS-CoV-2 infected subjects with mild/moderate symptoms (419 in Japan and 9 in South Korea).
